Although doctors and pharmacistsh́ave yet to figure out how

Laura Davis[1], Jeffrey Romero, Jason Becker, Martin Johnson, Michael Rose

[1]National Institute of Technology Rourkela

January 2013

Figure 1: a man and a woman posing for a picture .

Although doctors and pharmacistsh́ave yet to figure out how to relieve increased risk of Host-induced Entomological Syphilis that can result from rodent-borne pathogens such as Epidemic H1N1, a new study published today in the journal BMC Infectious Diseases (BID), says that it proves more achievable the new treatment may be.

The study uses an InVivo-Induced Antigen Therapeutic Eta1 (Ida1) vaccine to treat stem-cell-derived Aids in mice, which the Vivo-Induced Antigen Therapeutic Eta1 vaccine is still under development.

"Health professionals who are studying stem-cell-derived vaccines or treatment with guinea pigs will consider applying Ida1 therapy in a novel way to alleviating physiological and vaccine-induced Epidemic H1N1 SBS-related exposure to these SBS-related vectors," said lead author Wen-Jiang Zheng, a senior on the Research Department at the Honsenberg School of Medicine at the University of South Carolina and one of the authors of the study.

The researchers say the resulting vaccines could prevent severe stomach or sinus infections, for example, since they do not require blood transfusions, and the vaccines also protect and immunize the same amount of blood previously expelled from the intestines. When researchers use Ida1 therapy to treat Epidemic H1N1 SBS-related SBS-related infections, their new immunotherapy method may one day be more effective in treating similar diseases, such as inflammation, inflammation and haemorrhaging in the bloodstream, the researchers say.

About 25.7 million people in the U.S. have been diagnosed with infection related to the avian flu virus in this yearś influenza season. An estimated 44 million were exposed to the flu from the yearś first influenza pandemic, A.I.H.A. flu, and subsequent flu outbreak led by influenza A influenza virus and Influenza A.

The research team also includes scientist Yuan-Yeong Dai, professor of hepatology and hepatology at the University of South Carolina, and microbiologist Mei-Jie Po, adjunct professor of immunology at University of Southern California.

The new study sheds light on why you should always test for HPV and sepsis infections when you are considering a STI immunotherapy that could potentially reduce the risk of debilitating viral infections.

"If you ask your doctors whether you want to treat VIVI with semen or sepsis or with HIV, those questions will probably be answered, as they actually have to deal with these things," Wen-Jiang explained.

This study was supported by grants from the National Institutes of Health, the National Center for Biomedical Biopharmaceutical Research, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the National Science Foundation, the Department of Homeland Security, the National Institute of Neurological Disorders and Stroke, and the National Institutes of Health.

Article: Extended Opportunities to target sexually transmitted diseases and the lack of alternative therapies for prevention, Wen-Jiang Zheng, Yong-Hua Hu, Bo-Guang Sun, Wen-Jiang Zheng, Li Sun, Wen-Hua Hu, Bo-Guang Sun, Miguel Theroux, and Yun-Jiang Zheng; Jing-Yeong Dai, UCLA and Seoul National Medical University, Seoul, Korea; Wei-Shen Liu, University of Southern California, UCLA; Yuan-Yeong Dai, University of Southern California, UCLA; Shen-Yeong Dai, University of Southern California, UCLA; Ying-Teo Lam, Shanghai National University, Shanghai, China; Xiang-Yeong Xiao, Shanghai National University, Shanghai, China; Xiao-Won Li, Shanghai National Univer-

sity, Shanghai, China; and Zhou-wein U, Peking University, Beijing, China.
Image: Yong-Jang Hen (Image Credit: Zheng Zheng).